R&D Directions provides insight into pharmaceutical research and development, from
discovery through clinical trials and submission. Leaving the hard science to other publications,
R&D Directions focuses on pharmaceutical companies’ R&D business strategies and decisions.
Editorial content covers drugs, therapeutic categories, industry segments, and strategies, and
imparts extensive intelligence on products in the pipeline. Although
R&D Directions contains a
wealth of medical and scientific information, it is written in a non-clinical, non-technical style.
R&D Directions is read by senior managers, clinical trials managers, clinical drug and
academic researchers, medical directors, data and project management, marketing
and clinical monitoring professionals, along with regulatory affairs, drug safety, and quality control professionals. These
professionals represent pharmaceutical and biotechnology companies, clinical study sites, clinical labs, medical device
manufacturers, academic research institutions, data management firms, government agencies, and contract research
organizations, among others.
With a total circulation of more than 12,000*,
R&D Directions reaches more than 7,200* readers in pharmaceutical and
biotechnology companies; more than 40% of them are senior managers.* These subscribers are key decision makers and
constitute a prime audience for your marketing communications message.
Since
R&D Directions is the only publication of its kind targeting business professionals in research and development
environments, the magazine provides a unique medium for your marketing message.
ADVANCE NEWSLETTERS
The
Med Ad News and
R&D Directions Advance e-newsletters provide a unique opportunity to supplement
your monthly print advertising program. Each newsletter contains a preview, written by our editors, of
articles to be published in the upcoming issue. These e-newsletters provide the opportunity to reach more
than 25,000 industry professionals with your marketing message prior to being viewed in the print magazine.
* (December 2006 BPA Statement)
